Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

The year had a lot to celebrate, but there were certain pop culture occasions that had us cringing Alex Apatoff is the Managing Editor, Special Integrated Products at People, where she has worked for ...

The good, the bad and the WTF style moments celebrities served up this week Catherine Santino is a Style Writer-Reporter at PEOPLE. She began as a contributor for PEOPLE in 2022 and joined the staff ...

Minnie Mouse tells you that the Phonograph the Fairy Godmother enchanted seems to be having issues. Head to her home and take a picture of the problem. Speak with the Fairy Godmother. She will thank ...

Gear-obsessed editors choose every product we review. We may earn commission if you buy from a link. Why Trust Us? The Paris Climate Accords in 2015 set an ambitious (and necessary) goal of keeping ...

TIOBE Index for December 2025: Top 10 Most Popular Programming Languages Your email has been sent December’s TIOBE Index lands with a quieter top tier but a livelier shuffle just beneath it. The main ...